Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Approval | 2 | 2024 | 66 | 1.780 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2021 | 46 | 1.430 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2019 | 117 | 1.190 |
Why?
|
| Medication Adherence | 2 | 2019 | 138 | 1.100 |
Why?
|
| HIV Infections | 6 | 2023 | 835 | 1.040 |
Why?
|
| Pregnant Women | 4 | 2019 | 41 | 1.010 |
Why?
|
| Neoplasms | 4 | 2024 | 3035 | 0.980 |
Why?
|
| Orphan Drug Production | 1 | 2023 | 4 | 0.920 |
Why?
|
| Wilms Tumor | 1 | 2023 | 38 | 0.900 |
Why?
|
| Economics, Pharmaceutical | 1 | 2023 | 10 | 0.900 |
Why?
|
| Counseling | 4 | 2019 | 163 | 0.830 |
Why?
|
| Patient Handoff | 1 | 2023 | 95 | 0.810 |
Why?
|
| Text Messaging | 1 | 2022 | 31 | 0.790 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 144 | 0.770 |
Why?
|
| Internship and Residency | 2 | 2023 | 1041 | 0.760 |
Why?
|
| Genetic Therapy | 1 | 2023 | 370 | 0.750 |
Why?
|
| Enterobacter aerogenes | 1 | 2020 | 1 | 0.740 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 195 | 0.730 |
Why?
|
| Sexual Partners | 3 | 2018 | 100 | 0.720 |
Why?
|
| Bacteremia | 1 | 2020 | 102 | 0.680 |
Why?
|
| Self Efficacy | 1 | 2019 | 54 | 0.660 |
Why?
|
| Biomedical Research | 1 | 2023 | 398 | 0.660 |
Why?
|
| United States Food and Drug Administration | 3 | 2024 | 133 | 0.660 |
Why?
|
| Emotions | 1 | 2022 | 349 | 0.650 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 73 | 0.650 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 155 | 0.640 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 635 | 0.600 |
Why?
|
| Educational Measurement | 1 | 2019 | 231 | 0.580 |
Why?
|
| Sepsis | 1 | 2020 | 319 | 0.550 |
Why?
|
| Malawi | 7 | 2023 | 7 | 0.540 |
Why?
|
| Education, Medical | 1 | 2019 | 243 | 0.530 |
Why?
|
| Rotavirus Infections | 1 | 2016 | 12 | 0.530 |
Why?
|
| Christianity | 1 | 2016 | 37 | 0.530 |
Why?
|
| Rural Health Services | 1 | 2016 | 17 | 0.530 |
Why?
|
| Community Health Workers | 1 | 2016 | 33 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 257 | 0.500 |
Why?
|
| Community Health Services | 1 | 2016 | 82 | 0.490 |
Why?
|
| United States | 5 | 2024 | 6955 | 0.470 |
Why?
|
| Health Promotion | 1 | 2016 | 163 | 0.470 |
Why?
|
| Vaccination | 1 | 2016 | 273 | 0.450 |
Why?
|
| Humans | 22 | 2024 | 89063 | 0.410 |
Why?
|
| Mass Screening | 4 | 2019 | 636 | 0.350 |
Why?
|
| Cohort Studies | 3 | 2023 | 2863 | 0.330 |
Why?
|
| Pregnancy | 7 | 2023 | 3009 | 0.310 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 424 | 0.280 |
Why?
|
| Tenofovir | 2 | 2023 | 9 | 0.250 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2612 | 0.230 |
Why?
|
| Industry | 1 | 2023 | 17 | 0.230 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2023 | 38 | 0.230 |
Why?
|
| Tanzania | 1 | 2023 | 47 | 0.230 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 73 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 55 | 0.220 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 48 | 0.210 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 54 | 0.210 |
Why?
|
| Patient Compliance | 1 | 2023 | 230 | 0.200 |
Why?
|
| Language | 1 | 2023 | 154 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2023 | 229 | 0.200 |
Why?
|
| Lymphoma | 1 | 2023 | 265 | 0.200 |
Why?
|
| Adult | 7 | 2022 | 26507 | 0.200 |
Why?
|
| Premature Birth | 1 | 2023 | 117 | 0.200 |
Why?
|
| Child | 2 | 2023 | 7149 | 0.190 |
Why?
|
| Benzoxazines | 1 | 2021 | 5 | 0.190 |
Why?
|
| Cyclopropanes | 1 | 2021 | 25 | 0.190 |
Why?
|
| Alkynes | 1 | 2021 | 18 | 0.190 |
Why?
|
| Enterobacter | 1 | 2020 | 2 | 0.190 |
Why?
|
| Empathy | 1 | 2022 | 150 | 0.180 |
Why?
|
| Caregivers | 1 | 2022 | 159 | 0.180 |
Why?
|
| Breast Feeding | 1 | 2021 | 102 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2022 | 779 | 0.170 |
Why?
|
| Licensure, Medical | 1 | 2019 | 20 | 0.170 |
Why?
|
| Female | 9 | 2023 | 46011 | 0.170 |
Why?
|
| Serologic Tests | 1 | 2019 | 43 | 0.170 |
Why?
|
| Retrospective Studies | 2 | 2023 | 9003 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2022 | 385 | 0.170 |
Why?
|
| Climate | 1 | 2019 | 58 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 395 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2023 | 382 | 0.160 |
Why?
|
| AIDS Serodiagnosis | 1 | 2018 | 26 | 0.160 |
Why?
|
| HIV Seropositivity | 1 | 2018 | 51 | 0.160 |
Why?
|
| Chicago | 1 | 2023 | 1423 | 0.160 |
Why?
|
| Communication | 1 | 2022 | 457 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2023 | 2476 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 434 | 0.150 |
Why?
|
| Students | 1 | 2019 | 169 | 0.150 |
Why?
|
| Condoms | 1 | 2017 | 38 | 0.150 |
Why?
|
| Infant | 3 | 2023 | 3147 | 0.150 |
Why?
|
| Directive Counseling | 1 | 2017 | 35 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1043 | 0.140 |
Why?
|
| Competency-Based Education | 1 | 2017 | 36 | 0.140 |
Why?
|
| Prenatal Care | 1 | 2017 | 77 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 58 | 0.140 |
Why?
|
| Young Adult | 4 | 2022 | 6288 | 0.140 |
Why?
|
| Social Support | 1 | 2018 | 208 | 0.140 |
Why?
|
| Goals | 1 | 2017 | 67 | 0.140 |
Why?
|
| Zambia | 1 | 2016 | 9 | 0.130 |
Why?
|
| Disclosure | 1 | 2017 | 110 | 0.130 |
Why?
|
| Clinical Clerkship | 1 | 2017 | 118 | 0.130 |
Why?
|
| Rural Population | 1 | 2016 | 143 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2017 | 684 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 786 | 0.120 |
Why?
|
| Diarrhea | 1 | 2016 | 182 | 0.120 |
Why?
|
| Public Health | 1 | 2016 | 137 | 0.120 |
Why?
|
| Adolescent | 3 | 2022 | 9237 | 0.120 |
Why?
|
| Logistic Models | 1 | 2017 | 1212 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 2552 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 2411 | 0.110 |
Why?
|
| Students, Medical | 1 | 2017 | 418 | 0.100 |
Why?
|
| Sister Chromatid Exchange | 1 | 2011 | 13 | 0.100 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 17 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2017 | 780 | 0.100 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 66 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1706 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2011 | 261 | 0.090 |
Why?
|
| DNA Repair | 1 | 2011 | 362 | 0.080 |
Why?
|
| Male | 5 | 2021 | 42251 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4273 | 0.060 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 13 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2023 | 669 | 0.040 |
Why?
|
| Peer Group | 1 | 2018 | 81 | 0.040 |
Why?
|
| Safe Sex | 1 | 2017 | 24 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2017 | 48 | 0.040 |
Why?
|
| Workplace | 1 | 2017 | 29 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1223 | 0.040 |
Why?
|
| Family | 1 | 2018 | 325 | 0.030 |
Why?
|
| Medical Staff, Hospital | 1 | 2017 | 108 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 334 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 291 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1063 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 285 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1855 | 0.030 |
Why?
|
| RecQ Helicases | 1 | 2011 | 7 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2011 | 31 | 0.020 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2011 | 34 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 56 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2011 | 73 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 82 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2011 | 73 | 0.020 |
Why?
|
| Camptothecin | 1 | 2011 | 193 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 285 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2495 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 11737 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 27317 | 0.010 |
Why?
|